找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問(wèn)微社區(qū)

打印 上一主題 下一主題

Titlebook: Dyslipidemias in Kidney Disease; Adrian Covic,Mehmet Kanbay,Edgar V. Lerma Book 2014 Springer Science+Business Media New York 2014 Dialysi

[復(fù)制鏈接]
樓主: Extraneous
11#
發(fā)表于 2025-3-23 11:07:44 | 只看該作者
Book 2014e latest clinical evidence and management guidance for patients of various demographics and stages of chronic kidney disease. Written for the nephrologist community, as well as cardiologists and general practitioners, this guide will provide practical knowledge and fill a much needed void in the literature..
12#
發(fā)表于 2025-3-23 17:10:12 | 只看該作者
Environmental Resources Limitedn hemodialysis and peritoneal dialysis patients, and even in kidney transplant recipients. These abnormalities contribute to the risk of cardiovascular disease in these patients. Moreover, dyslipidemia may adversely affect the progression of renal disease in patients with CKD.
13#
發(fā)表于 2025-3-23 20:15:35 | 只看該作者
14#
發(fā)表于 2025-3-24 00:57:51 | 只看該作者
Hans Wu?ing,D. Goetz,I. Jahn,Hans Wu?ingrecommended. Pharmacological intervention with statin therapy is recommended based on results from the ALERT study, although there is a reluctance to prescribe these agents in transplant recipients due to risk of side effects and drug interactions.
15#
發(fā)表于 2025-3-24 06:09:20 | 只看該作者
Epidemiology/Prevalence of Dyslipidemia in the General Population and in Patients with Chronic Kidnn hemodialysis and peritoneal dialysis patients, and even in kidney transplant recipients. These abnormalities contribute to the risk of cardiovascular disease in these patients. Moreover, dyslipidemia may adversely affect the progression of renal disease in patients with CKD.
16#
發(fā)表于 2025-3-24 07:08:07 | 只看該作者
Pharmacokinetics of Lipid-Lowering Medications in Chronic Kidney Disease,chapter is to discuss the pharmacokinetic and pharmacodynamic properties of lipid-lowering drugs in patients with chronic kidney disease, those on dialysis, and patients following renal transplantation. This chapter will also discuss the safety, drug dosing, and drug interactions that are important in this group of patients.
17#
發(fā)表于 2025-3-24 14:43:17 | 只看該作者
Dyslipidemia in the Kidney Transplant Patient,recommended. Pharmacological intervention with statin therapy is recommended based on results from the ALERT study, although there is a reluctance to prescribe these agents in transplant recipients due to risk of side effects and drug interactions.
18#
發(fā)表于 2025-3-24 18:35:18 | 只看該作者
https://doi.org/10.1007/978-1-4939-0515-7Dialysis; Dyslipidemias; Geriatric Patient; Hyperlipidemia; Kidney Disease; Lipid Metabolism; Lipid Nephro
19#
發(fā)表于 2025-3-24 21:48:00 | 只看該作者
20#
發(fā)表于 2025-3-25 02:26:49 | 只看該作者
Adrian Covic,Mehmet Kanbay,Edgar V. LermaComprehensive resource that fills a significant knowledge gap.Features the latest clinical evidence and management guidance.Chapters authored by leaders in the field.Includes supplementary material:
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛(ài)論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-12 13:10
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
武夷山市| 城步| 思南县| 云霄县| 自贡市| 法库县| 泸州市| 汝阳县| 吉林省| 通渭县| 中江县| 明溪县| 桐梓县| 乐至县| 安西县| 茌平县| 包头市| 东莞市| 普洱| 宁化县| 尼木县| 嘉鱼县| 宁夏| 绥中县| 武汉市| 武宣县| 水富县| 泽州县| 翁牛特旗| 同德县| 安化县| 灵台县| 云林县| 斗六市| 湟中县| 巴塘县| 牟定县| 赤壁市| 南京市| 双江| 六枝特区|